JP Morgan Chase
SPRY icon

JP Morgan Chase’s ARS Pharmaceuticals SPRY Stock Holding History

JP Morgan Chase’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.11M Sell
363,316
-19,485
-5% -$168K ﹤0.01% 3857
2026
Q1 		$2.99M Sell
382,801
-34,289
-8% -$329K ﹤0.01% 3778
2025
Q4 		$4.86M Buy
417,090
+382,031
+1,090% +$3.72M ﹤0.01% 3335
2025
Q3 		$352K Buy
35,059
+499
+1% +$7.16K ﹤0.01% 5221
2025
Q2 		$603K Buy
34,560
+2,357
+7% +$34K ﹤0.01% 4679
2025
Q1 		$405K Buy
32,203
+1,091
+4% +$13.1K ﹤0.01% 4900
2024
Q4 		$328K Sell
31,112
-1,710
-5% -$23.9K ﹤0.01% 5254
2024
Q3 		$476K Sell
32,822
-178
-0.5% -$2.12K ﹤0.01% 4924
2024
Q2 		$281K Sell
33,000
-17,183
-34% -$152K ﹤0.01% 4971
2024
Q1 		$513K Buy
50,183
+15,534
+45% +$116K ﹤0.01% 4781
2023
Q4 		$190K Buy
34,649
+369
+1% +$1.62K ﹤0.01% 5413
2023
Q3 		$130K Buy
34,280
+11,746
+52% +$77.1K ﹤0.01% 5328
2023
Q2 		$151K Buy
22,534
+19,612
+671% +$131K ﹤0.01% 5251
2023
Q1 		$19K Buy
2,922
+350
+14% +$2.69K ﹤0.01% 5986
2022
Q4 		$22K Buy
2,572
+461
+22% +$2.99K ﹤0.01% 5860
2022
Q3 		$11K Buy
2,111
+614
+41% +$3.03K ﹤0.01% 5946
2022
Q2 		$6K Sell
1,497
-12,261
-89% -$42.8K ﹤0.01% 6131
2022
Q1 		$49K Sell
13,758
-158,066
-92% -$688K ﹤0.01% 5806
2021
Q4 		$1.14M Buy
171,824
+122,174
+246% +$993K ﹤0.01% 4278
2021
Q3 		$495K Buy
49,650
+40,555
+446% +$1M ﹤0.01% 4733
2021
Q2 		$281K Sell
9,095
-19,255
-68% -$617K ﹤0.01% 5058
2021
Q1 		$1.24M Buy
+28,350
New +$1.34M ﹤0.01% 4074

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase's SPRY Position: Q2 2026 in Review

JP Morgan Chase reduced its ARS Pharmaceuticals (SPRY) stake by 5.1% in Q2 2026, selling an estimated $168K and leaving 363,316 shares worth $3.11M. The position accounts for ﹤0.01% of the portfolio, ranked #3857.

JP Morgan Chase first reported a position in SPRY in Q1 2021 and has held it in 22 quarters since. The position peaked at $4.86M in Q4 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • JP Morgan Chase held 363,316 shares of ARS Pharmaceuticals worth $3.11M as of Q2 2026.
  • JP Morgan Chase sold 19,485 ARS Pharmaceuticals shares in Q2 2026, an estimated $168K.
  • ARS Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3857 holding.
  • JP Morgan Chase first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • JP Morgan Chase's ARS Pharmaceuticals position peaked at $4.86M in Q4 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.